ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.

Prostate Cancer

Christopher Sweeney, MBBS

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

Breast Cancer

Julie Gralow, MD and Clifford A. Hudis, MD

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Multiple Myeloma

Saad Usmani, MD

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).

Oct

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer

Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers